Ref: HNL/SEC/2026-27/18 **Date: 13.08.2026**

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Scrip Code: 544785

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra-Kurla
Complex, Bandra (E), Mumbai- 400 051.
NSE Symbol: HEXAGON

Re: HEXAGON NUTRITION LIMITED – ISIN: INE0JUI01012

Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")-Media Release

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of the Listing Regulations, please find enclosed herewith the Earnings Release for the Financial Results for the quarter ended June 30, 2026.

The disclosure will also be available on the Company's website at www.hexagonnutrition.com
This is for your information and records.

Thanking you,

For and on behalf of Hexagon Nutrition Limited

VEDANTI SWAPNIL VARTAK
Digitally signed by VEDANTI SWAPNIL VARTAK
Date: 2026.08.13 16:14:19 +05'30'

Ms. Vedanti Vartak
Designation: Company Secretary & Compliance Officer
ICSI Membership Number: A41580

Encl: As above

Q1 FY27 Earnings Release

Hexagon Nutrition reports Q1 FY27 revenue of ₹104.3 crore, up 43.2% YoY; PAT grows 25.1% to ₹8.1 crore

Company's first quarterly results as a listed entity following its June 2026 IPO; EBITDA up 17.3% YoY to ₹11.8 crore

Mumbai, August 12, 2026: Hexagon Nutrition Limited ("Hexagon" or "the Company"), a leading global nutrition company engaged in the manufacturing and marketing of micronutrient premixes, therapeutic nutrition products, clinical nutrition, food fortification solutions and consumer nutrition products today announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27) — its first quarterly disclosure since listing on the BSE and NSE in June 2026.

The company reported revenue from operations of ₹104.3 crore in Q1 FY27, up 43.2% from ₹72.9 crore in Q1 FY26. EBITDA rose 17.3% year-on-year to ₹11.8 crore, with an EBITDA margin of 11.3%, compared to 13.8% in the corresponding quarter last year. Profit after tax grew 25.1% YoY to ₹8.1 crore, with a PAT margin of 7.7% against 8.9% in Q1 FY26

Key Consolidated Financial Summary (in cr's)

Particulars (₹ Crore)	Q1 FY27	Q1 FY26	YoY	FY26	FY25	YoY
Revenue from Operations	104.3	72.9	43.2%	382.6	324.9	17.8%
EBITDA	11.8	10.1	17.3%	52.9	40.1	31.9%
EBITDA Margin	11.3%	13.8%	(250 bps)	13.8%	12.3%	+150 bps
Profit After Tax (PAT)	8.1	6.5	25.1%	37.9	24.3	56.1%
PAT Margin	7.7%	8.9%	(120 bps)	9.9%	7.5%	+240 bps
Basic EPS (₹)	0.67	0.58	15.5%	3.43	1.75	96.0%
Diluted EPS (₹)	0.66	0.53	24.5%	3.09	1.57	96.8%

EBITDA has been computed as Profit before Tax + Finance Cost + Depreciation & Amortisation less Other Income.

Financial Highlights – Q1 FY27

- Revenue from Operations stood at Rs. 104.3 crore, registering a 43.2% YoY growth compared with Rs. 72.9 crore in Q1 FY26.
- Gross Profit stood at Rs. 45.8 crore, up 34.1% YoY from Rs. 34.1 crore.

- EBITDA stood at Rs. 11.8 crore, registering 17.3% YoY growth compared with Rs. 10.1 crore.
- EBITDA margin stood at 11.3%.
- Profit Before Tax stood at Rs. 10.6 crore, up 25.1% YoY.
- Profit After Tax stood at Rs. 8.1 crore, registering 25.1% YoY growth compared with Rs. 6.5 crore.
- PAT margin stood at 7.7%.

Commenting on the performance, Mr. Arun Kelkar, Chairman & Executive Director, "We have started FY27 with strong revenue momentum, with consolidated revenue from operations growing 43.2% year-on-year to Rs. 104.3 crore. This performance reflects the continued demand for our nutrition solutions and the progress we are making across our domestic and international markets.

Our focus remains on building a diversified and scalable nutrition platform across Micronutrient Premixes, Clinical Nutrition and Therapeutic Nutrition. We continue to see significant opportunities in international markets, supported by our presence across more than 70 countries, as well as in the growing clinical and functional nutrition segments.

As we enter this new phase as a listed company, our priorities remain unchanged — sustainable revenue growth, stronger international presence, innovation-led product development, operational efficiency and disciplined capital allocation. We remain confident in the long-term opportunity for Hexagon Nutrition and are committed to creating sustainable value for all our stakeholders".

About Hexagon Nutrition Limited:

Hexagon Nutrition Limited is a leading integrated nutrition company engaged in the development, manufacturing and marketing of nutritional products across multiple categories including micronutrient premixes, therapeutic nutrition, clinical nutrition, food fortification, consumer nutrition and specialised nutrition solutions.

The Company serves customers across India and several international markets through its diversified portfolio catering to food manufacturers, pharmaceutical companies, healthcare institutions and consumers. Hexagon's manufacturing facilities are supported by strong research and development capabilities, enabling the Company to develop innovative nutrition solutions aligned with evolving global healthcare and nutrition trends.

The Company operates four manufacturing facilities across India and Uzbekistan, with facilities located in Nashik, Maharashtra; Chennai and Thoothukudi, Tamil Nadu; and Tashkent, Uzbekistan. It has a global presence through its subsidiaries and offices across India, South Africa, Uzbekistan and Hong Kong.

For more information, please contact:

ADFACTORS PR
Reputation & Critical Issues Advisory

Adfactors PR Private Limited (Investor Relations)

Saloni Nagvekar: saloni.nagvekar@adfactorspr.com / Yashita Shetty: Yashita.shetty@adfactorspr.com